NCT03191539View on ClinicalTrials.gov

Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis

PHASE3UnknownINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 2, 2017

Primary Completion Date

June 14, 2019

Study Completion Date

June 14, 2019

Conditions
Arthritis; Psoriasis (Etiology)
Interventions
DRUG

Apremilast

30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER

NCT03191539 - Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis | Biotech Hunter | Biotech Hunter